E
Eli Lilly
Discovery, development, manufacture, and sale of products in pharmaceutical products business segment
About Eli Lilly
Eli Lilly and Company, commonly known as Lilly, is a global pharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that improve lives. Founded over 140 years ago, Lilly has a rich history of scientific breakthroughs, including the development of the first life-saving treatment for diabetes, insulin. The company operates in the healthcare and pharmaceutical market, focusing on creating treatments for various medical conditions.
Lilly serves a diverse range of clients, including healthcare professionals, hospitals, clinics, and patients worldwide. The company’s business model revolves around extensive research and development (R&D) to create new medicines, followed by manufacturing and distributing these products globally. Lilly invests heavily in R&D to discover new treatments and improve existing ones, ensuring they meet the highest standards of safety and efficacy.
The company makes money primarily through the sale of its prescription medicines. These products are sold to healthcare providers, who then prescribe them to patients. Lilly’s portfolio includes treatments for diabetes, cancer, immunology, pain management, and other serious health conditions. Additionally, Lilly collaborates with various partners, including Team USA, to promote health and wellness initiatives.
Lilly is also vigilant about protecting its products from counterfeiting and ensuring the availability of its medicines, such as tirzepatide and dulaglutide, which are crucial for managing diabetes. The company emphasizes its commitment to ethical practices, stating that it never asks for money in exchange for employment or investment opportunities.
In summary, Lilly is a leading pharmaceutical company dedicated to making life better through innovative medical solutions, serving a global market with a focus on quality and ethical standards.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1876
- Headquarters
- Indianapolis, United States
- Listing
- IPO 1952
- Employees
- 57,609
- Open positions
- 791
- Dealroom signal
- 93.0/100
- Industry
- Health
- Sector
- Health, Biotechnology, Drug Development, Weight Management, Metabolism, Biotech and Pharma, Horizon Europe
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 193 companies, latest Sep 2026
- Capital deployed
- $9B
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Apr 2026 | $0 | — | Elser Financial Planning | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2025 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Eli Lilly is 750K monthly website visits, up 13.6% over the last three months. Eli Lilly's team grew 16.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Moonwalk BiosciencesSouth San Francisco, United StatesAdipose-targeted RNAi medicines for obesity and cardiometabolic disease
$280Mvaluation
CloverleafbioNew Haven, United StatesEngineered tRNA therapeutics for cancer
$132Mvaluation
Superluminal MedicinesBoston, United StatesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created
$240Mvaluation
BigHat BiosciencesSan Mateo, United StatesProtein therapeutics company that develops an antibody design platform guided by artificial intelligence
$300Mvaluation
ATAI Life SciencesBerlin, GermanyA biotechnology company pioneering mental health innovation
$2.8Bvaluation
Kura OncologySan Diego, United StatesA clinical-stage biopharmaceutical company developing precision medicines for the treatment of solid tumors and blood cancers
$487Mvaluation
Circle PharmaSouth San Francisco, United StatesEarly stage biotechnology company applying proprietary
$370Mvaluation
Merida BiosciencesCambridge, United StatesPrecision immunology leader developing targeted therapies for autoimmune and allergic disorders
$2.9Bvaluation
InduProSeattle, United StatesGet closer to our groundbreaking work in proximity based therapeutics
$308Mvaluation
AmplificaSan Diego, United StatesA biopharmaceutical company focused on developing novel treatments to address androgenic alopecia (hair loss)
$104Mvaluation
Remedium bioNeedham, United StatesAdjustable, single-injection gene therapies for durable protein expression
$40Mvaluation
AdvanCellSydney, AustraliaRadiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment
$1.3Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
HHS Administration for Strategic Preparedness and Response
Series B and later1 investor entered at this stage
Elser Financial Planning
Other known investors5 additional known investors
BioAdvance
Kleiner Perkins
TVM Capital Life Science
UnLtd Spain
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Eli Lilly on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eli Lilly’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.